Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).

导出 OA

翻译打印收藏纠错

作者： Aminah,Jatoi ^[1] ; Shaker R,Dakhil ; Jeff A,Sloan ; John W,Kugler ; Kendrith M,Rowland ; Paul L,Schaefer ; Paul J,Novotny ; Donald B,Wender ; Howard M,Gross ; Charles L,Loprinzi ; North Central Cancer Treatment Group

作者单位： Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Jatoi.aminah@mayo.edu ^[1]

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗菌药(Anti-Bacterial Agents);抗肿瘤药(Antineoplastic Agents);双盲法(Double-Blind Method);药疹(Drug Eruptions);女(雌)性(Female);人类(Humans);发病率(Incidence);男(雄)性(Male);中年人(Middle Aged);生活质量(Quality of Life);疾病严重程度指数(Severity of Illness Index);四环素(Tetracycline)

DOI 10.1007/s00520-010-0988-5

PMID 20820817

发布时间 2024-06-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览6

Supportive care in cancer

2011年19卷10期

1601-7页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).

Supportive care in cancer

相似文献

Supportive care in cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).

Supportive care in cancer

相似文献

Supportive care in cancer

相关期刊

检索历史清除